These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 11200888)

  • 1. ESR dosimetry of 89Sr and 153Sm in bone.
    Kinoshita A; Braga FJ; Graeff CF; Baffa O
    Appl Radiat Isot; 2001 Feb; 54(2):269-74. PubMed ID: 11200888
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Samarium-153 EDTMP therapy of disseminated skeletal metastasis.
    Turner JH; Martindale AA; Sorby P; Hetherington EL; Fleay RF; Hoffman RF; Claringbold PG
    Eur J Nucl Med; 1989; 15(12):784-95. PubMed ID: 2483138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Radionuclide therapy for painful bone metastases].
    Szefer J; Zuchora Z
    Wiad Lek; 2004; 57(5-6):280-3. PubMed ID: 15518077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Strontium 89 therapy for the palliation of pain due to osseous metastases.
    Robinson RG; Preston DF; Schiefelbein M; Baxter KG
    JAMA; 1995 Aug; 274(5):420-4. PubMed ID: 7542352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radiation safety considerations for the bone seeking radiopharmaceuticals. 89SrCl2, 186Re-HEDP and 153Sm-EDTMP.
    Lam MG; Hoekstra A; de Klerk JM; van Rijk PP; Zonnenberg BA
    Nuklearmedizin; 2009; 48(1):37-43. PubMed ID: 19212610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Samarium-153-labelled EDTMP for bone metastases from cancer of the prostate.
    Sandeman TF; Budd RS; Martin JJ
    Clin Oncol (R Coll Radiol); 1992 May; 4(3):160-4. PubMed ID: 1375094
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dosimetry and toxicity of samarium-153-EDTMP administered for bone pain due to skeletal metastases.
    Bayouth JE; Macey DJ; Kasi LP; Fossella FV
    J Nucl Med; 1994 Jan; 35(1):63-9. PubMed ID: 7505819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radiopharmaceutical therapy of bone metastases with 89SrCl2, 186Re-HEDP and 153Sm-EDTMP: a dosimetric study using Monte Carlo simulation.
    Strigari L; Sciuto R; D'Andrea M; Pasqualoni R; Benassi M; Maini CL
    Eur J Nucl Med Mol Imaging; 2007 Jul; 34(7):1031-8. PubMed ID: 17237963
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective 153Sm-EDTMP therapy dosimetry by whole-body scintigraphy.
    Cameron PJ; Klemp PF; Martindale AA; Turner JH
    Nucl Med Commun; 1999 Jul; 20(7):609-15. PubMed ID: 10423762
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Samarium-153-EDTMP biodistribution and dosimetry estimation.
    Eary JF; Collins C; Stabin M; Vernon C; Petersdorf S; Baker M; Hartnett S; Ferency S; Addison SJ; Appelbaum F
    J Nucl Med; 1993 Jul; 34(7):1031-6. PubMed ID: 7686217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radionuclides for metastatic bone pain palliation: a need for rational re-evaluation in the new millennium.
    Krishnamurthy GT; Krishnamurthy S
    J Nucl Med; 2000 Apr; 41(4):688-91. PubMed ID: 10768570
    [No Abstract]   [Full Text] [Related]  

  • 12. A phase I study of samarium-153 ethylenediaminetetramethylene phosphonate therapy for disseminated skeletal metastases.
    Turner JH; Claringbold PG; Hetherington EL; Sorby P; Martindale AA
    J Clin Oncol; 1989 Dec; 7(12):1926-31. PubMed ID: 2585026
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multicentre trial on the efficacy and toxicity of single-dose samarium-153-ethylene diamine tetramethylene phosphonate as a palliative treatment for painful skeletal metastases in China.
    Tian JH; Zhang JM; Hou QT; Oyang QH; Wang JM; Luan ZS; Chuan L; He YJ
    Eur J Nucl Med; 1999 Jan; 26(1):2-7. PubMed ID: 9933654
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Marrow irradiation with high-dose 153Samarium-EDTMP followed by chemotherapy and hematopoietic stem cell infusion for acute myelogenous leukemia.
    Rodriguez V; Anderson PM; Litzow MR; Erlandson L; Trotz BA; Arndt CA; Khan SP; Wiseman GA
    Leuk Lymphoma; 2006 Aug; 47(8):1583-92. PubMed ID: 16966270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Skeletal uptake and soft-tissue retention of 186Re-HEDP and 153Sm-EDTMP in patients with metastatic bone disease.
    Brenner W; Kampen WU; Kampen AM; Henze E
    J Nucl Med; 2001 Feb; 42(2):230-6. PubMed ID: 11216521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New research developments increase therapeutic options for thyroid cancer and bone pain palliation.
    Williams JE
    J Nucl Med; 1997 Nov; 38(11):19N-20N, 26N. PubMed ID: 9374327
    [No Abstract]   [Full Text] [Related]  

  • 17. Dose response relationship and multiple dose efficacy and toxicity of samarium-153-EDTMP in metastatic cancer to bone.
    Alberts AS; Smit BJ; Louw WK; van Rensburg AJ; van Beek A; Kritzinger V; Nel JS
    Radiother Oncol; 1997 May; 43(2):175-9. PubMed ID: 9192964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Our experience on pain palliation of bone metastasis with Sr-89 or Sm-153 in cancer patients resistant to a conventional analgesic therapy. A retrospective study.
    Montesano T; Giacomobono S; Acqualagna G; Colandrea M; Di Nicola A; Travascio L; Giancamerla M; D'Apollo R; Toteda M; Ugolini F; Filesi M; Ronga G
    Clin Ter; 2009; 160(3):193-9. PubMed ID: 19756320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Samarium-153-EDTMP in bone metastases.
    Ahonen A; Joensuu H; Hiltunen J; Hannelin M; Heikkilä J; Jakobsson M; Jurvelin J; Kairemo K; Kumpulainen E; Kulmala J
    J Nucl Biol Med (1991); 1994 Dec; 38(4 Suppl 1):123-7. PubMed ID: 7543288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The importance of BMI in dosimetry of
    Fallahpoor M; Abbasi M; Asghar Parach A; Kalantari F
    Appl Radiat Isot; 2017 Jun; 124():1-6. PubMed ID: 28284122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.